J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

The approved ANDA is therapeutically equivalent to GlaxoSmithKline LLC's Lamictal XR extended-release tablets in strength of ...

Alembic has a cumulative total of 216 ANDA approvals (188 final approvals and 28 tentative approvals) from USFDA.

Dr. David Holbrook brings a wealth of experience to the MitoRx board with a background spanning global business development at leading companies such as GlaxoSmithKline and Roche, and extensive ...

The stock hits an intraday high on Thursday, October 3, 2024, after getting approval from USFDA for general medication drug.

Vadodara: Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug ...

This approval adds to Alembic Pharma's growing portfolio, which now includes 216 ANDA approvals from the USFDA, comprising ...

The estimated market value for Lamotrigine Extended-Release Tablets is approximately $163 million for the year ending June ...

Mary Kennedy and GSK Ireland launch Respiratory Syncytial Virus (RSV) awareness campaign encouraging over 65s and at-risk ...

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Lamotrigine Extended-Release Tablets USP, 200 mg, 250 ...

Patient advocacy groups are often funded through pharmaceutical companies, but there are currently no regulations governing ...

Tiburon resident Dr. John A. Clements, a titan in the field of pulmonary biology whose research was revolutionary in treating ...